Milos Miljkovic Sells 932 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insider Milos Miljkovic sold 932 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $16.72, for a total value of $15,583.04. Following the completion of the transaction, the insider now owns 36,341 shares in the company, valued at $607,621.52. This represents a 2.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Milos Miljkovic also recently made the following trade(s):

• On Monday, January 6th, Milos Miljkovic sold 948 shares of Cartesian Therapeutics stock. The shares were sold at an average price of $16.83, for a total value of $15,954.84.
• On Thursday, November 14th, Milos Miljkovic sold 35,000 shares of Cartesian Therapeutics stock. The stock was sold at an average price of $16.13, for a total value of $564,550.00.

Cartesian Therapeutics Trading Down 1.4 %

RNAC opened at $16.92 on Friday. The firm’s fifty day simple moving average is $19.08 and its 200 day simple moving average is $18.13. The stock has a market capitalization of $430.02 million, a P/E ratio of -0.32 and a beta of 0.56. Cartesian Therapeutics, Inc. has a 12 month low of $11.66 and a 12 month high of $41.87.

Institutional Trading of Cartesian Therapeutics

Institutional investors have recently modified their holdings of the company. FMR LLC raised its position in Cartesian Therapeutics by 458.3% in the 3rd quarter. FMR LLC now owns 2,851,830 shares of the company’s stock valued at $45,972,000 after buying an additional 2,341,054 shares during the last quarter. Great Point Partners LLC bought a new position in shares of Cartesian Therapeutics during the 3rd quarter worth approximately $3,224,000. Logos Global Management LP bought a new position in shares of Cartesian Therapeutics during the 2nd quarter worth approximately $2,431,000. Marshall Wace LLP acquired a new stake in shares of Cartesian Therapeutics in the second quarter valued at approximately $811,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Cartesian Therapeutics in the second quarter worth $351,000. 86.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on RNAC shares. Cantor Fitzgerald raised shares of Cartesian Therapeutics to a “hold” rating in a research note on Monday, December 2nd. Needham & Company LLC reissued a “buy” rating and issued a $41.00 price target on shares of Cartesian Therapeutics in a report on Tuesday, December 3rd. BTIG Research began coverage on shares of Cartesian Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $42.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 target price (up from $41.00) on shares of Cartesian Therapeutics in a report on Wednesday, December 4th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.86.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.